Gastrin and cholecystokinin receptor ligands (III)
Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently -N-, -N(R5)-(R5 being selected from H, Me, Et, Pr, Bn, OH and -CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), -CH-, -O- or -S-; n is from 1 t...
Gespeichert in:
Hauptverfasser: | , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | LOW CAROLINE MINLI RACHEL KALINDJIAN SARKIS BARRET BUCK ILDIKO MARIA TOZER MATTHEW JOHN |
description | Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently -N-, -N(R5)-(R5 being selected from H, Me, Et, Pr, Bn, OH and -CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), -CH-, -O- or -S-; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an -O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is -CO-NH-SO2-Ph, -SO2-NH-CO-PH, -CH2OH, or a group of the formula -R7U, (wherein U is -COOH, tetrazolyl, -CONHOH or -SO3H; and R7 is a bond; C1 to C6 hydrocarbylene optionally substituted by hydroxy, amino or acetamido; -O-(C1 to C3 alkylene)-; -SO2NR8-CHR9-; -CO-NR8-CHR9-, R8 and R9 being independently selected from H and methyl; or -NH-(CO)c-CH2, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US7034048B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US7034048B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US7034048B23</originalsourceid><addsrcrecordid>eNrjZDByTywuKcrMU0jMS1FIzsjPSU2uLC7Jz87MA4oVpSanFpTkFynkZKYD5YsVNDw9PTV5GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakl8aLC5gbGJgYmFk5ExEUoAVeIrUg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Gastrin and cholecystokinin receptor ligands (III)</title><source>esp@cenet</source><creator>LOW CAROLINE MINLI RACHEL ; KALINDJIAN SARKIS BARRET ; BUCK ILDIKO MARIA ; TOZER MATTHEW JOHN</creator><creatorcontrib>LOW CAROLINE MINLI RACHEL ; KALINDJIAN SARKIS BARRET ; BUCK ILDIKO MARIA ; TOZER MATTHEW JOHN</creatorcontrib><description>Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently -N-, -N(R5)-(R5 being selected from H, Me, Et, Pr, Bn, OH and -CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), -CH-, -O- or -S-; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an -O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is -CO-NH-SO2-Ph, -SO2-NH-CO-PH, -CH2OH, or a group of the formula -R7U, (wherein U is -COOH, tetrazolyl, -CONHOH or -SO3H; and R7 is a bond; C1 to C6 hydrocarbylene optionally substituted by hydroxy, amino or acetamido; -O-(C1 to C3 alkylene)-; -SO2NR8-CHR9-; -CO-NR8-CHR9-, R8 and R9 being independently selected from H and methyl; or -NH-(CO)c-CH2, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2006</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20060425&DB=EPODOC&CC=US&NR=7034048B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20060425&DB=EPODOC&CC=US&NR=7034048B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LOW CAROLINE MINLI RACHEL</creatorcontrib><creatorcontrib>KALINDJIAN SARKIS BARRET</creatorcontrib><creatorcontrib>BUCK ILDIKO MARIA</creatorcontrib><creatorcontrib>TOZER MATTHEW JOHN</creatorcontrib><title>Gastrin and cholecystokinin receptor ligands (III)</title><description>Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently -N-, -N(R5)-(R5 being selected from H, Me, Et, Pr, Bn, OH and -CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), -CH-, -O- or -S-; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an -O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is -CO-NH-SO2-Ph, -SO2-NH-CO-PH, -CH2OH, or a group of the formula -R7U, (wherein U is -COOH, tetrazolyl, -CONHOH or -SO3H; and R7 is a bond; C1 to C6 hydrocarbylene optionally substituted by hydroxy, amino or acetamido; -O-(C1 to C3 alkylene)-; -SO2NR8-CHR9-; -CO-NR8-CHR9-, R8 and R9 being independently selected from H and methyl; or -NH-(CO)c-CH2, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2006</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDByTywuKcrMU0jMS1FIzsjPSU2uLC7Jz87MA4oVpSanFpTkFynkZKYD5YsVNDw9PTV5GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakl8aLC5gbGJgYmFk5ExEUoAVeIrUg</recordid><startdate>20060425</startdate><enddate>20060425</enddate><creator>LOW CAROLINE MINLI RACHEL</creator><creator>KALINDJIAN SARKIS BARRET</creator><creator>BUCK ILDIKO MARIA</creator><creator>TOZER MATTHEW JOHN</creator><scope>EVB</scope></search><sort><creationdate>20060425</creationdate><title>Gastrin and cholecystokinin receptor ligands (III)</title><author>LOW CAROLINE MINLI RACHEL ; KALINDJIAN SARKIS BARRET ; BUCK ILDIKO MARIA ; TOZER MATTHEW JOHN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US7034048B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2006</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>LOW CAROLINE MINLI RACHEL</creatorcontrib><creatorcontrib>KALINDJIAN SARKIS BARRET</creatorcontrib><creatorcontrib>BUCK ILDIKO MARIA</creatorcontrib><creatorcontrib>TOZER MATTHEW JOHN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LOW CAROLINE MINLI RACHEL</au><au>KALINDJIAN SARKIS BARRET</au><au>BUCK ILDIKO MARIA</au><au>TOZER MATTHEW JOHN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Gastrin and cholecystokinin receptor ligands (III)</title><date>2006-04-25</date><risdate>2006</risdate><abstract>Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently -N-, -N(R5)-(R5 being selected from H, Me, Et, Pr, Bn, OH and -CH2COOR6, wherein R6 represents H, Me, Et, Pr or Bn), -CH-, -O- or -S-; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; R1 is H or C1 to C15 hydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; R2 is selected from H, Me, Et, Pr and OH, each R2 being independently selected from H, Me, Et, Pr and OH when n is greater than 1; R3 (when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each R3 is independently selected from H, Me, Et and Pr, or two R3 groups on neighbouring carbon atoms are linked to form a C3 to C6 carbocylic ring, or two R3 groups are absent from neighbouring carbon atoms which are linked by a double bond; or R2 and R3 on the same carbon atom together represent an -O group; R4 is C1 to C15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is -CO-NH-SO2-Ph, -SO2-NH-CO-PH, -CH2OH, or a group of the formula -R7U, (wherein U is -COOH, tetrazolyl, -CONHOH or -SO3H; and R7 is a bond; C1 to C6 hydrocarbylene optionally substituted by hydroxy, amino or acetamido; -O-(C1 to C3 alkylene)-; -SO2NR8-CHR9-; -CO-NR8-CHR9-, R8 and R9 being independently selected from H and methyl; or -NH-(CO)c-CH2, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_US7034048B2 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | Gastrin and cholecystokinin receptor ligands (III) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T00%3A13%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LOW%20CAROLINE%20MINLI%20RACHEL&rft.date=2006-04-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS7034048B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |